US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy information.
The investigational MDMA therapeutic developed by Lykos was previously submitted to the FDA under the new drug application (NDA) designation in May 2024. However, the FDA Advisory Committee have since stated that the therapeutic cannot be approved due to concerns surrounding the manner in which the clinical trial was conducted. The Advisory Committee claims that there was a lack of documentation around whether trial participants abused the drug, as well as issues around the trial design.
In a complete response letter (CRL) published by Lykos, the company have raised issues regarding the committee’s request. “The FDA request for another study is deeply disappointing,” commented Lykos CEO Amy Emerson. “While conducting another phase III study would take several years, we still maintain that many of the requests that had been previously discussed with the FDA and raised at the Advisory Committee meeting can be addressed with existing data, post-approval requirements, or through reference to the scientific literature.” Among the concerns raised by the FDA include collected endpoint data at 18 weeks, where draft guidance for psychedelic drugs indicates endpoint data to be collected at 12 weeks. Lykos had also previously aligned with the regulator in the Special Protocol Assessment in 2017 on a number of measures to reduce bias in the study design. For example, prior MDMA use among trial participants were not seen as detrimental, with almost 30% of participants in phase II studies reporting prior use of MDMA. These parameters were all shared with the FDA before establishing phase III trial inclusion and exclusion criteria under the Special Protocol Assessment established.
Lykos have raised their own concerns regarding the Advisory Committee’s lack of subject matter experts on the panel, as well as the nature of their discussions which went beyond the scientific content in the briefing documents.
The novel approach of psychedelic drug therapy in tandem with psychotherapy was raised as a concern by the committee as well. Some on the panel questioned whether the combination was necessary. While Lykos acknowledged the novel drug-therapy combined approach, the company stated that it will remain committed to developing this integrated approach. Emerson commented “Our heart breaks for the millions of military veterans, first responders, victims of sexual and domestic abuse, and countless others suffering from PTSD who may now face more years without access to new treatment options. We intend to work tirelessly and use all available regulatory pathways to find a reasonable and expeditious path forward for patients who deserve access to midomafetamine-assisted therapy for PTSD.”
Source:
Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD [Accessed August 12, 2024] https://www.prnewswire.com/news-releases/lykos-therapeutics-announces-complete-response-letter-for-midomafetamine-capsules-for-ptsd-302219182.html
Related News
-
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Alzheimer’s drug Leqembi rejected by EU drug regulator
The European Medicine’s Agency (EMA), the drug regulator for the EU, rejected Eisai and Biogen’s Alzheimer’s drug product Leqembi, citing the drug’s slowing of cognitive decline did not outweigh the risk of serious brain swellin... -
News Second obesity drug candidate from Roche shows early trial success
Following from its purchase of Carmot Therapeutics, Roche have announced positive early-stage trial success for its second obesity drug candidate acquired from Carmot Therapeutics. -
News Tumour microproteins could provide basis for cancer vaccines
A recent study published in Science Advances has identified a set of microproteins produced exclusively in liver tumours, which may provide a clear target for the development of a cancer vaccine. -
News Reworked once-daily weight-loss pill from Pfizer to progress
American pharmaceutical giant Pfizer have continued with a reworked version of their weight-loss pill danuglipron, progressing with a once-daily version of the pill.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance